Development and Manufacturing of New APIs: Leveraging Experience, Technological Innovation, and Present Vision to Future Success

Development and Manufacturing of New APIs: Leveraging Experience, Technological Innovation, and Present Vision to Future Success

Wednesday, October 9, 2024 12:45 PM to 1:10 PM · 25 min. (Africa/Abidjan)
Hall 5 - 5B49
Manufacturing 5.0
Product Innovation

Information

In today’s globalized economy, international integration plays a crucial role in the development of new molecules. This integration encompasses various aspects, including the transfer of production activities and the utilization of past experiences._x000D_ _x000D_ _x000D_ • Risk and Innovation: The development of APIs (active pharmaceutical ingredients) utilizes innovative process techniques and potentially hazardous chemical reactions. Leveraging past experiences is essential to mitigate risks and optimize production._x000D_ _x000D_ • Solid-State Development: A deep understanding of solid-state properties is critical for API manufacturers. Solid-state characterization ensures product stability, bioavailability, and manufacturability.

Dipharma FrancisThe Dipharma Group is a global CDMO and a leading manufacturer of APIs, New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering about 40 APIs with DMFs registered worldwide. Thanks to a workforce of about 600 skilled and highly committed employees, supported by four state-of-the-art CGMP facilities, located in the U.S.A. and Italy, plus commercial sales offices in Italy, the U.S.A. and China, Dipharma is strategically positioned to meet the dynamic needs of the pharmaceutical industry. Our fully-equipped Research and Development Centers, supported by the internal Intellectual Property department, drive innovation by developing cutting-edge chemical processes and crystalline forms tailored to meet the unique requirements of our customers. Since 1970, Dipharma has managed to achieve a positive unbroken record of inspections by the major Regulatory Agencies and the CGMP manufacturing sites are equipped to supply quantities from laboratory to industrial scale, covering the entire lifecycle of a pharmaceutical substance. Dipharma's core technologies are: High-pressure hydrogenation, Nitration, Nitroesterification, Azide chemistry, Borane reductions, Cross-coupling reactions, Curtius reaction, Dissolving metal reduction, Enzymatic chemistry, Epichlorohydrin chemistry, Hoffman reaction, Hydrogen peroxide oxidations, Carbohydrate chemistry, Enantioselective reactions, Use of nitroalkanes (Henry reaction), Wolff-Kishner reduction. The Dipharma Group has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently while offering flexibility and agility to promptly solve any challenge. Experience you can trust

Registered attendees

Agnieszka Bis
Agnieszka Bis
Team Leader Regulatory Affairs CMCmAbxience
AR
Alain Ruys
Strategic ConsultantMasco Group
AF
Alberto Faido
Global Sales DirectorDipharma Francis Srl

Log in

See all the content and easy-to-use features by logging in or registering!